Wahi a kahi noiʻi hou i paʻi ʻia ma ka Journal of the Endocrine Society, ua ʻike kahi mea noiʻi e hoʻonui ka testosterone i ka hopena o ka maʻi prostate a hoʻonui i nā hopena o ka hoʻolaha ʻana i nā kemika carcinogenic i nā ʻiole. Ua koi ʻo ia i nā kāne i ʻike ʻole ʻia me ka hypogonadism E makaʻala i ka wā e lawelawe ana i ka lāʻau testosterone. ʻO ka endocrinology.
I nā makahiki he ʻumi i hala iho nei, ua hoʻonui ʻia ka hoʻohana ʻana o ka testosterone ma waena o nā kāne ʻelemakule e ʻimi nei e hoʻonui i ka ikehu a ʻoi aku ka ʻōpio. Ua ʻike ʻia kahi haʻawina i paʻi ʻia ma ka Journal of Clinical Endocrinology and Metabolism ʻoiai nā hopohopo e pili ana i nā pilikia cardiovascular, ʻo ka nui o nā kāne ʻAmelika e hoʻomaka ana i ka testosterone therapy ua aneane ʻehā mai ka makahiki 2000.
The Endocrine Society’s clinical practice guidelines for the treatment of testosterone in adult men recommend that testosterone be prescribed only for men with significantly low hormone levels, decreased libido, erectile dysfunction, or other symptoms of hypogonadism. Online: http://www.endocrine.org/~/ media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Androgens-in-Men-Standalone.pdf
"Ke hōʻike nei kēia haʻawina i ka testosterone ponoʻī he carcinogen nāwaliwali i nā ʻiole kāne," wahi a ka mea kākau o ka noiʻi a me Kauka Maarten C. Bosland o DVSc mai ke Kulanui o Illinois ma Chicago. "Ke hui pū ʻia me nā kemika carcinogenic, hana ka testosterone i kahi kūpono no ka ulu ʻana o ka maʻi tumora. Inā hoʻokumu ʻia kēia mau ʻike i nā kānaka, a laila e lilo nā pilikia olakino i kumu koʻikoʻi.
Ua nānā ʻia nā haʻawina pane pane ʻelua i ka loaʻa ʻana o ka maʻi maʻi prostate i nā ʻiole. Hāʻawi ʻia nā ʻiole i ka testosterone ma o kahi mea hoʻopaʻa i hoʻokuʻu ʻia. Ma mua o ka hoʻokomo ʻana i ka testosterone i loko o nā ʻiole, ua hoʻokomo ʻia kekahi mau holoholona me ka kemika carcinogenic N-nitroso-N-methylurea (MNU). Ua hoʻohālikelike ʻia kēia mau ʻiole me kahi pūʻulu mana i loaʻa iā MNU akā ua hoʻokomo i kahi mea hoʻokuʻu hoʻokuʻu ʻole.
Ma waena o nā ʻiole i loaʻa i ka testosterone me ka ʻole o nā kemika carcinogenic, 10% a 18% i hoʻomohala i ka maʻi prostate. ʻAʻole i hoʻoulu ʻia ka lāʻau Testosterone wale nō i nā ʻōpū kikoʻī ma nā wahi ʻē aʻe, akā i ka hoʻohālikelike ʻia me nā ʻiole hoʻomalu, ua hoʻonui nui ʻia ka nui o nā ʻiole me nā maʻi maʻi maʻi ma kēlā me kēia pūnaewele. Ke ʻike ʻia nā ʻiole i ka testosterone a me nā carcinogens, ʻo kēia mālama ʻana ke kumu o 50% a 71% o nā ʻiole e hoʻomohala i ka maʻi prostate. ʻOiai inā he haʻahaʻa loa ka nui o ka hormone e hoʻonui ai i ke kiʻekiʻe o ka testosterone i loko o ke koko, ʻo ka hapalua o nā ʻiole e loaʻa mau i ka maʻi prostate. ʻO nā holoholona i ʻike ʻia i nā kemika carcinogenic akā ʻaʻole i ka testosterone ʻaʻole i hoʻomohala i ka maʻi prostate.
"No ka mea he mea hou ka hoʻomohala ʻana o ka testosterone therapy, a ʻo ka maʻi maʻi prostate kahi maʻi e ulu mālie nei, ʻaʻohe ʻikepili i kēia manawa e hoʻoholo ai inā hoʻonui ka testosterone i ka nui o ka maʻi prostate i nā kānaka," wahi a Boslan. "ʻOiai ua alakaʻi ʻia nā haʻawina kanaka, he mea naʻauao ke kaupalena ʻana i nā prescriptions testosterone i nā kāne me ka hypogonadism clinical symptomatic, a e pale aku i nā kāne e hoʻohana ana i ka testosterone no nā kumu lāʻau lapaʻau ʻole, me ka ʻōlelo ʻana i nā hōʻailona maʻamau o ka ʻelemakule."
Ua paʻi ʻia ka haʻawina i kapa ʻia ʻo "Testosterone therapy he mea hoʻoikaika maʻi maʻi no ka prostate rat" ma mua o ka paʻi ʻana.
E kiʻi i ka nūhou ʻepekema hou loa ma o ka leka uila manuahi a ScienceDaily, i hōʻano hou ʻia i kēlā me kēia lā a me kēlā me kēia pule. A i ʻole e nānā i ka hānai nūhou hou i kēlā me kēia hola ma kāu mea heluhelu RSS:
E haʻi mai iā mākou i kou manaʻo no ScienceDaily-aloha mākou i nā ʻōlelo maikaʻi a maikaʻi ʻole. Aia kekahi pilikia i ka hoʻohana ʻana i kēia pūnaewele? pilikia?
Ka manawa hoʻouna: Sep-09-2021